# A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression

> **NCT07686445** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Adlai Nortye Biopharma Co., Ltd.** · enrollment: 228 (estimated)

## Conditions studied

- Solid Tumor (Phase I)
- RAS Mutation
- CEACAM5

## Interventions

- **DRUG:** Intravenous AN4035
- **DRUG:** Intravenous AN4035 followed by intravenous EGFR Inhibitor.

## Key facts

- **NCT ID:** NCT07686445
- **Lead sponsor:** Adlai Nortye Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-23
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 228 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07686445

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07686445, "A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07686445. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*